Get the Daily Brief
Latest Biotech News
IPO momentum in AI-enabled RNAi and RNA therapeutics
City Therapeutics priced an initial public offering and is set to begin trading Friday as it builds out an “Alnylam 2.0” RNAi platform. The company’s $200M IPO adds another public-market listing...
FDA rare-disease review overhaul
The FDA said it plans to “reimagine” rare-disease therapy regulation through a Rare Disease Framework Initiative aimed at improving consistency and seeking external input. The agency’s approach...
Venture and capital formation for biotech pipelines
OMass Therapeutics closed an oversubscribed $310M Series C to advance its rare endocrinology and immunology pipeline toward the clinic. The round is designed to fund OMS1620 through Phase II...
Rare pediatric gene therapy monetization via FDA PRVs
Ultragenyx is selling a second rare pediatric Priority Review Voucher within a week, this time for $203M, following FDA approval of FAYUVI (rebisufligene etisparvovec-hopf). The transaction brings...
R&D dealmaking: Roche expands RNAi obesity pipeline in China
Roche reached an agreement with China-based Rona Therapeutics to secure worldwide rights to an ALK7-targeting RNAi candidate aimed at obesity and metabolic disease. The structure includes up to...
Clinical signals in oncology: durable responses in low-grade serous ovarian cancer
Regeneron presented initial clinical results at IGCS showing durable responses in advanced low-grade serous ovarian cancer (LGSOC) with ubamatamab. In a late-breaking plenary, the company reported...
AI-enabled diagnostics: preoperative cancer risk models gain trial-scale validation
A multicenter Chinese study reported an AI-based MRI nomogram that uses clinical features plus AI-derived “tumor habitat” signatures to predict high-risk hepatocellular carcinoma prior to surgery....
Therapeutics for rare pediatric neurology: sugar-based therapy for GLUT1 deficiency
A case report in the Journal of Neurology described oral L-fucose supplementation as a potential therapy for GLUT1 deficiency syndrome. The single patient showed biochemical correction and...
Drug safety and execution: CAPA signals on surgical imaging and treatment decision limits
A prospective, two-phase observer-performance study reported that a confidence-aware AI system improved radiologists’ accuracy and agreement in distinguishing two common benign parotid tumors on...
Regeneration and cell therapy: egg-cell inspired biomaterial protects islet cells from immune attack
A Nature Biomedical Engineering study described an “egg cell-inspired” biomaterial that shields insulin-producing islet cells after transplantation in diabetic mice. Researchers encapsulated donor...
Rare disease regulation reset at FDA
The FDA on Wednesday signaled a major shift in how it reviews rare disease therapies, launching the Rare Disease Framework Initiative. The agency said it will reassess existing policies and...
Rare disease biotech funding for ACTH-related and interferon programs
OMass Therapeutics raised an oversubscribed $310 million Series C round to advance its endocrinology and immunology pipeline toward later-stage development. The financing will primarily support...
AI-enabled siRNA collaboration targets obesity via ALK7 RNAi
Roche agreed to license an ALK7-targeting RNAi candidate from Rona Therapeutics, paying up to $100 million in upfront and early milestone payments for exclusive worldwide rights. Rona is also...
Phase 1 durability readout for self-amplifying mRNA H5N1 vaccine
A Phase 1 study of the self-amplifying mRNA H5N1 vaccine ARCT-2304 found that extending the dose interval strengthened antibody durability. In the trial, an eight-week spacing produced more robust...
Omics-linked prediction of immunotherapy response in lung cancer
An exploratory study linked circulating neutrophil states to both resistance and toxicity patterns in advanced lung cancer treated with immune checkpoint inhibitors. Researchers reported that...
First human target-engagement signals for CNS siRNA
Arrowhead’s brain shuttle milestone reported first human target-engagement data supporting systemic central nervous system delivery of an siRNA program targeting tau. Company disclosures indicate...
CAR-T durability signal in relapsed/refractory myeloma
In an early-phase study, BCMA-targeted CAR-T therapy anito-cel generated responses in all 38 treated participants with relapsed or refractory multiple myeloma. The report described a favorable...
FDA guidance shift for EMA trial advice continuity
The European Medicines Agency confirmed that an EU-level trial advice pilot will become a permanent option for sponsors. The change allows developers in the EU to continue seeking regulator...
New pooled evidence for guideline-adherent nurse care to reduce alcohol harm
A meta-analysis of sixteen randomized controlled trials found nurse-led interventions significantly reduced alcohol screening scores, consumption, and binge drinking in adults, while also noting...
IPO cash for AI oncology platform and discovery pipeline
Iambic Therapeutics launched into public markets with a $150 million IPO to accelerate clinical development of an oncology pipeline built from internally discovered programs. The company described...